WO2020132366A4 - Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés - Google Patents
Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés Download PDFInfo
- Publication number
- WO2020132366A4 WO2020132366A4 PCT/US2019/067676 US2019067676W WO2020132366A4 WO 2020132366 A4 WO2020132366 A4 WO 2020132366A4 US 2019067676 W US2019067676 W US 2019067676W WO 2020132366 A4 WO2020132366 A4 WO 2020132366A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- seq
- terminus
- cell
- epitope
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 157
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 141
- 229920001184 polypeptide Polymers 0.000 title claims abstract 140
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract 11
- 230000021615 conjugation Effects 0.000 title claims 19
- 238000000034 method Methods 0.000 title claims 5
- 208000008383 Wilms tumor Diseases 0.000 claims abstract 39
- 208000026448 Wilms tumor 1 Diseases 0.000 claims abstract 33
- 102100022748 Wilms tumor protein Human genes 0.000 claims abstract 33
- 101710127857 Wilms tumor protein Proteins 0.000 claims abstract 33
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract 6
- 201000008026 nephroblastoma Diseases 0.000 claims abstract 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract 4
- 206010009944 Colon cancer Diseases 0.000 claims abstract 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract 4
- 206010039491 Sarcoma Diseases 0.000 claims abstract 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract 4
- 206010006187 Breast cancer Diseases 0.000 claims abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract 3
- 206010027406 Mesothelioma Diseases 0.000 claims abstract 3
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract 3
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims abstract 3
- 208000022013 kidney Wilms tumor Diseases 0.000 claims abstract 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract 3
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 25
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 25
- 239000000126 substance Substances 0.000 claims 18
- 235000001014 amino acid Nutrition 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 12
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 9
- 108010052199 HLA-C Antigens Proteins 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 4
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 4
- 108010075704 HLA-A Antigens Proteins 0.000 claims 4
- 108010058607 HLA-B Antigens Proteins 0.000 claims 4
- 102000043129 MHC class I family Human genes 0.000 claims 4
- 108091054437 MHC class I family Proteins 0.000 claims 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- -1 CD86 Proteins 0.000 claims 2
- 102220485768 Glycophorin-A_S88C_mutation Human genes 0.000 claims 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 2
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 2
- 108010024164 HLA-G Antigens Proteins 0.000 claims 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 2
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010081208 RMFPNAPYL Proteins 0.000 claims 2
- 102220606888 Zinc finger protein Gfi-1b_E77C_mutation Human genes 0.000 claims 2
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 230000009144 enzymatic modification Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000002482 oligosaccharides Polymers 0.000 claims 2
- 235000016491 selenocysteine Nutrition 0.000 claims 2
- 150000003345 selenocysteines Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims 1
- 102000002627 4-1BB Ligand Human genes 0.000 claims 1
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 claims 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 claims 1
- 102000015212 Fas Ligand Protein Human genes 0.000 claims 1
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 claims 1
- 108010035233 HLA-A*34:01 antigen Proteins 0.000 claims 1
- 102220376554 HLA-B*4001 Human genes 0.000 claims 1
- 108010028440 HLA-B*46:01 antigen Proteins 0.000 claims 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 108010028921 Lipopeptides Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 108010001441 Phosphopeptides Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 102100032702 Protein jagged-1 Human genes 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des polypeptides multimères modulateurs des lymphocytes T ("T-Cell-MMP") comprenant un polypeptide immunomodulateur ("MOD") qui peuvent être sélectionnés pour présenter une affinité de liaison réduite à un polypeptide co-immunomodulateur parent ("Co-MOD") et un peptide de présentation d'épitope du tumeur de Wilms (WT-1) conjugué. Les conjugués lymphocyte T-MMP-épitope sont utiles pour moduler l'activité d'un lymphocyte T par administration de peptides immunomodulateurs, tels que des IL-2 ou des variants d'IL-2 qui présentent une affinité de liaison réduite à IL-2R, pour les lymphocytes T d'une manière sélective/spécifique d'un épitope WT-1, et par conséquent, pour le traitement d'individus, en particulier ceux atteints d'une leucémie myéloïde aigue, d'un myélome, d'un cancer de l'ovaire, d'un cancer du pancréas, d'un cancer du poumon non à petites cellules, d'un cancer colorectal, d'un cancer du sein, d'une tumeur de Wilms, d'un mésothéliome, d'un sarcome des tissus mous, d'un neuroblastome ou d'un néphroblastome.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/342,513 US20220008467A1 (en) | 2018-12-19 | 2021-06-08 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862782245P | 2018-12-19 | 2018-12-19 | |
US62/782,245 | 2018-12-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/342,513 Continuation US20220008467A1 (en) | 2018-12-19 | 2021-06-08 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2020132366A2 WO2020132366A2 (fr) | 2020-06-25 |
WO2020132366A3 WO2020132366A3 (fr) | 2020-07-23 |
WO2020132366A4 true WO2020132366A4 (fr) | 2020-09-24 |
Family
ID=71101640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/067676 WO2020132366A2 (fr) | 2018-12-19 | 2019-12-19 | Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés |
Country Status (2)
Country | Link |
---|---|
US (1) | US20220008467A1 (fr) |
WO (1) | WO2020132366A2 (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104684577B (zh) * | 2012-01-13 | 2018-05-08 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽及其使用方法 |
WO2018129474A1 (fr) * | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation |
-
2019
- 2019-12-19 WO PCT/US2019/067676 patent/WO2020132366A2/fr active Application Filing
-
2021
- 2021-06-08 US US17/342,513 patent/US20220008467A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020132366A3 (fr) | 2020-07-23 |
WO2020132366A2 (fr) | 2020-06-25 |
US20220008467A1 (en) | 2022-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020534352A5 (fr) | ||
Bryant et al. | In vitro and in vivo evaluation of cysteine rebridged trastuzumab–MMAE antibody drug conjugates with defined drug-to-antibody ratios | |
Hos et al. | Approaches to improve chemically defined synthetic peptide vaccines | |
Unger et al. | Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells | |
JP5612623B2 (ja) | 高親和性hivt細胞レセプター | |
JP2020533273A5 (fr) | ||
EA202091754A1 (ru) | Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака | |
WO2018189152A3 (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers | |
CN109963585A (zh) | 包括细胞穿透肽、多表位和tlr肽激动剂的用于治疗癌症的融合物 | |
CA2516702A1 (fr) | Recepteur des lymphocytes t modifie lie par une liaison disulfure entre les groupes du domaine cysteine constant | |
WO2013036574A4 (fr) | Formes modifiées d'exotoxine a de pseudomonas | |
EP4035675A3 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
PH12021550205A1 (en) | Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods | |
JP2020143084A (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
EP3725327A3 (fr) | Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse | |
PH12021550346A1 (en) | B*44 restricted peptides for use in immunotherapy against cancers and related methods | |
IL147766A0 (en) | Therapeutic compounds comprised of anti-fc receptor binding agents | |
PH12021550581A1 (en) | Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods | |
Galaine et al. | Heparan sulfate proteoglycans promote telomerase internalization and MHC class II presentation on dendritic cells | |
PH12020552013A1 (en) | A*03 restricted peptides for use in immunotherapy against cancers and related methods | |
WO2020132368A4 (fr) | Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés | |
WO2020132366A4 (fr) | Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés | |
PH12020551958A1 (en) | Peptides for use in immunotherapy against cancers | |
CR20210329A (es) | Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados | |
EA202190572A1 (ru) | Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19899709 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19899709 Country of ref document: EP Kind code of ref document: A2 |